Clinical value of prostate segmentation and volume determination on MRI in benign prostatic hyperplasia
PDF
Cite
Share
Request
Abdominal Imaging - Review
P: 229-233
May 2014

Clinical value of prostate segmentation and volume determination on MRI in benign prostatic hyperplasia

Diagn Interv Radiol 2014;20(3):229-233
1. Molecular Imaging Program, National Cancer Institute, NIH, Bethesda, Maryland, USA
2. Center for Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
3. Urologic Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA
4. iCAD Inc. (S.P.), Nashua, New Hampshire, USA
No information available.
No information available
Received Date: 21.10.2013
Accepted Date: 01.11.2013
PDF
Cite
Share
Request

ABSTRACT

Benign prostatic hyperplasia (BPH) is a nonmalignant pathological enlargement of the prostate, which occurs primarily in the transitional zone. BPH is highly prevalent and is a major cause of lower urinary tract symptoms in aging males, although there is no direct relationship between prostate volume and symptom severity. The progression of BPH can be quantified by measuring the volumes of the whole prostate and its zones, based on image segmentation on magnetic resonance imaging. Prostate volume determination via segmentation is a useful measure for patients undergoing therapy for BPH. However, prostate segmentation is not widely used due to the excessive time required for even experts to manually map the margins of the prostate. Here, we review and compare new methods of prostate volume segmentation using both manual and automated methods, including the ellipsoid formula, manual planimetry, and semiautomated and fully automated segmentation approaches. We highlight the utility of prostate segmentation in the clinical context of assessing BPH.